Eli Lilly asked the FDA to broaden the use of Zepbound to include obstructive sleep apnea.
New drug tirzepatide shows promise in improving obstructive sleep apnea symptoms.
The results were published in the New England Journal of Medicine and presented at an American Diabetes Association conference.
Tirzepatide is in the same class of medications as Ozempic and is sold under the brand names Mounjaro and Zepbound.
Two clinical trials showed that tirzepatide significantly improved symptoms of obstructive sleep apnea in people with obesity.
New research indicates that tirzepatide, the compound in Zepbound, improves symptoms of obstructive sleep apnea. Two major new clinical trials showed that tirzepatide, which is in the same class of medications as Ozempic and is sold under the brand names Mounjaro and Zepbound, significantly improved symptoms of obstructive sleep apnea in people with obesity. The results were published Friday in a paper in the New England Journal of Medicine and presented at an American Diabetes Association conference in Orlando, Fla. Eli Lilly, which makes tirzepatide and funded the studies, said it had asked the Food and Drug Administration to broaden the use of the Zepbound to include obstructive sleep apnea. If approved, it would become the first drug specifically cleared to treat the condition, and would give patients another option for managing their sleep apnea. Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe to The Times.
A popular obesity drug, Tirzepatide, may help treat sleep apnea.
Eli Lilly and Co. has asked the FDA to expand Tirzepatide’s use to treat moderate to severe sleep apnea.
Patients taking Tirzepatide lost between 18% and 20% of their body weight on average.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(80%)
The article reports on new research that shows a popular weight loss drug, tirzepatide, may help treat severe sleep apnea. The author provides details about the study and its findings, including the reduction in breathing episodes per hour for patients taking tirzepatide compared to those taking a dummy drug. However, the article also includes editorializing and opinions from experts that go beyond reporting facts. For example, Dr. Atul Malhotra is quoted as saying that tirzepatide is a 'more effective knife in the drawer' for treating sleep apnea. This statement adds an unnecessary emotional element to the article and could be seen as an attempt to manipulate readers' emotions or perceptions of the drug. Additionally, Dr. Sanjay Patel expresses caution about whether tirzepatide can be used as a sole treatment for obstructive sleep apnea and raises concerns about cost and access. These opinions are not directly related to the study findings and could potentially sway readers' opinions on the drug without providing additional facts or evidence.
Dr. Sanjay Patel, a sleep medicine specialist at the University of Pittsburgh, cautioned that whether tirzepatide can treat sleep apnea in real-world patients 'remains unclear' because of the way improvement is measured.
The new research shows that tirzepatide is 'a more effective knife in the drawer,' for treating sleep apnea, said lead author Dr. Atul Malhotra, a sleep medicine specialist at the University of California, San Diego.
Eli Lilly applied for U.S. approval of its weight loss drug Zepbound for the treatment of obstructive sleep apnea and expects a decision as early as the end of the year.
,
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The article contains some instances of appeals to authority and inflammatory rhetoric, but no formal or dichotomous fallacies are present. The author quotes experts and uses their opinions to support the validity of Zepbound's potential for treating obstructive sleep apnea. However, these quotes do not constitute fallacies as they accurately represent the positions of those being quoted.
][Annika Kim Constantino] We're super excited... I think it actually went beyond what most external experts were hoping for.[//
Tirzepatide significantly reduced the number of breathing interruptions during sleep for clinically obese people living with moderate-to-severe obstructive sleep apnea.
Some patients improved to such an extent that they may no longer require CPAP therapy.
Lilly announced preliminary results from the trial in April and plans to submit data to regulatory agencies with a view to expanding tirzepatide’s label to include treating sleep apnea.
1 billion people are estimated to be living with obstructive sleep apnea worldwide. In the US, 80 million people have the condition, 20 million of whom have moderate-to-severe OSA.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(95%)
The article contains an appeal to authority with the statement 'Lilly announced preliminary results from the trial in April and said tirzepatide reduced sleep apnea severity by nearly two-thirds.' This implies that Lilly's announcement is evidence of the drug's effectiveness, but it does not provide any information about the study design or results. Additionally, there are some instances of inflammatory rhetoric with phrases like 'potential gamechanger', 'significant but hidden', and 'critical'. However, these do not significantly impact the overall argument or reasoning of the article.
Lilly announced preliminary results from the trial in April and said tirzepatide reduced sleep apnea severity by nearly two-thirds.
Tirzepatide, a medication in weight-loss drug Zepbound and diabetes treatment Mounjaro, may help treat sleep apnea by reducing its severity along with weight and improving blood pressure.
Eli Lilly has asked the FDA to expand Tirzepatide's use for treating moderate to severe sleep apnea; a decision is expected by year-end.
In a study of nearly 500 patients diagnosed with obesity and sleep apnea, tirzepatide reduced the number of breathing episodes during sleep by about half to nearly 60% compared to a placebo.
Patients on tirzepatide lost between 18% and 20% of their body weight and showed improvements in blood pressure and other health measures.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(35%)
The article is moderately deceptive due to selective reporting and editorializing. The author highlights the potential for tirzepatide to treat sleep apnea without mentioning that the drug has not yet been approved for this use by the FDA. Additionally, while it is true that patients who took tirzepatide lost weight and experienced improvements in blood pressure, these improvements are implied as direct results of taking the drug rather than linking to peer-reviewed studies which have not been retracted.
A popular obesity drug may help treat a dangerous disorder in which people struggle to breathe while they sleep, a new study finds.
